Stockscreener 앱 받기
1.475
8.26%
0.1125
시간 외 거래:
1.48
0.005
+0.34%
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
Neuropathic Ocular Pain Market Expected to Experience Major - openPR.com
Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum - Barchart.com
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Decrease in Short Interest - Defense World
ADS Program collapse - Investegate
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - marketscreener.com
OKYO moves toward FDA talks after eye drug trial – ICYMI - Proactive Investors
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease - Investegate
Small cap wrap: GoviEx, NextSource Materials, Voyageur Pharmaceuticals, OKYO Pharma... - Proactive Investors
FDA grants fast track to OKYO Pharma’s neuropathic pain drug By Investing.com - Investing.com Nigeria
FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain - Ophthalmology Times
FDA grants fast track to OKYO Pharma’s neuropathic pain drug - Investing.com
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain - TipRanks
FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition - Stock Titan
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain - Proactive Investors
OKYO Pharma accelerates neuropathic corneal pain treatment with early closure of Phase 2 trial - Proactive Investors
Market movers: Snap, Super Micro Computer, OKYO Pharma... - Proactive Investors
Okyo Pharma announces plans to accelerate development of urcosimod - TipRanks
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain - TipRanks
OKYO Pharma speeds up NCP drug development - Investing.com
OKYO Pharma Announces Plans to Accelerate the Clinical - GlobeNewswire
OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain - Proactive Investors
Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN
Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news
OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive Investors
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com India
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
OKYO Pharma confirms stability of drug candidate - Investing.com
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive Investors
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World
Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - marketscreener.com
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment | NASDAQ:OKYO - Proactive Investors
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive Investors
0.39%
3.66%
자본화:
|
볼륨(24시간):